Potential use of psilocybin drugs in the treatment of depression
Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, Andrzej Pilc
Expert Opinion on Emerging Drugs October 2, 2023 DOI: 10.1080/14728214.2023.2264180 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Anxiety Depression Psilocybin Psychedelic-assisted therapy |
| Keywords | Psychedelics Mental health Depression treatment Psilocybin research Clinical studies |
| Citations | 4 |
| Key findings | Psilocybin has shown promising results in phase I-II trials for depression, but phase III trials are required to confirm efficacy and safety. |
Abstract
Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to confirm its efficacy and safety and to change the way it is perceived by physicians and patients.